Evidence map›Paper›PMID 39035001›Full record

ReviewFrontiers in immunology2024

Implications of MHC-restricted immunopeptidome in transplantation.

Zhuldyz Zhanzak, Davide Cina, Aileen C Johnson, Christian P Larsen

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zhuldyz ZhanzakDepartment of Surgery, Emory University School of Medicine, Atlanta, GA, United States.
Davide CinaDepartment of Surgery, Emory University School of Medicine, Atlanta, GA, United States.
Aileen C JohnsonDepartment of Surgery, Emory University School of Medicine, Atlanta, GA, United States.
Christian P LarsenDepartment of Surgery, Emory University School of Medicine, Atlanta, GA, United States.

Funding

Selective CD28 Blockade in Renal Transplant RecipientsU01AI138909 · NIAID · EMORY UNIVERSITY · PI BADELL, IDELBERTO RAUL, FORD, MANDY L · 2018 to 2022
$4.9M
NIAID NIH HHS U01 AI138909
6 · The paper itself

Abstract

The peptide presentation by donor and recipient major histocompatibility complex (MHC) molecules is the major driver of T-cell responses in transplantation. In this review, we address an emerging area of interest, the application of immunopeptidome in transplantation, and describe the potential opportunities that exist to use peptides for targeting alloreactive T cells. The immunopeptidome, the set of peptides presented on an individual's MHC, plays a key role in immune surveillance. In transplantation, the immunopeptidome is heavily influenced by MHC-derived peptides, delineating a key subset of the diverse peptide repertoire implicated in alloreactivity. A better understanding of the immunopeptidome in transplantation has the potential to open up new approaches to identify, characterize, longitudinally quantify, and therapeutically target donor-specific T cells and ultimately support more personalized immunotherapies to prevent rejection and promote allograft tolerance.

Indexed as

Graft RejectionPeptidesAnimalsAntigen PresentationHumansMajor Histocompatibility ComplexOrgan TransplantationT-LymphocytesPeptidesdirect allorecognitionimmunopeptidomeindirect allorecognitiontolerancetransplantation

Identifiers

PMID39035001
PMCPMC11257886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.